ClinicalTrials.gg
RecruitingNCT06684613Updated Sep 4, 2026

Integrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health Clinics

A Phase 2 interventional study of PrEP Decision Aid and Generic Information in Sexual Risk Behavior for HIV-infection and Reproductive Health, sponsored by Yale University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Yale University · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in HIV Infections by Yale University — 2 open to participants now, 3 under way, none of them phase 3. HIV Infections · Yale University.

Planned enrollment
18th of 27
50 · median 60
Started
2026
with 1 other
Phase 2
4 of 30
1 open now
Registered
29th of 30
by date

Among the 30 studies in HIV Infections by Yale University, this one is the 18th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 29th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

2 of the 30 studies in HIV Infections by Yale University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in HIV Infections by Yale University, or all of them as a file.
02

Study summary

This study addresses the need for HIV prevention to be integrated into counseling visits at sexual and reproductive health clinics.

Read the detailed description

The purpose of this study is to expand and enhance a PrEP decision aid to include the full array of available formulation options and then integrate its delivery into sexual and reproductive health settings during counseling visits, where PrEP can be provided to all women who are interested. Rooted in health implementation frameworks, this study evaluates health and implementation determinants simultaneously along: 1) innovation characteristics; 2) clinical encounter; 3) recipients; and 4) context.

In Aim 1, patients (n=15-20), clinicians (n=10), and staff (n=10) at sexual and reproductive health clinics across Greater New Haven, CT will be engaged for semi-structured interviews to expand and enhance an existing PrEP decision aid to include all available formulations and optimize its integration into sexual and reproductive health clinics. Qualitative interviews will inform infrastructure development to support PrEP delivery in sexual and reproductive health clinics.

In Aim 2 (a hybrid Type 2 effectiveness-implementation study), patients will be randomized (n=50) to receive either the PrEP decision aid or generic PrEP information prior to a clinician visit. In follow-up interviews immediately post-visit, and at Months 3 and 6, primary outcomes are clinical efficacy (PrEP initiation) and implementation (using Proctor definitions for feasibility, acceptability, penetration, and adoption) that are important for future planned scale-up.

03

Conditions studied

  • Sexual Risk Behavior for HIV-infection
  • Reproductive Health

Keywords

  • HIV Prevention
  • PrEP
  • sexual reproductive health
  • woman
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Patients (inclusion):

  • Woman
  • Aged 18 years or older
  • Have a uterus
  • Do not have (by self-report)
  • Not currently on PrEP
  • Comfortable conversing in English or Spanish
  • Able to participate in procedures

Patients (exclusion):

  • People who cannot become pregnant (i.e., have had a hysterectomy or tubal ligation)
  • People who wish to become pregnant (will not qualify for pregnancy prevention counseling)
  • Have a scheduled visit with a member of the investigative team (to minimize risk of potential ascertainment bias)
  • Participants of Aim 1 cannot participate in Aim 2.

Sexual and Reproductive Health clinicians will be included if they provide sexual and reproductive health patient care at any of the participating sites. Clinic staff will be included if they work at any of the participating sites and have patient-facing or non-patient-facing roles .

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    PrEP Decision Aid

    Participants randomized to the decision aid (active intervention arm), will interact with the enhanced PrEP decision aid in REDCap. This is an individualized, patient-facing decision aid that supports informed patient choice and is interactive. In contrast to shared decision aids that guide a clinical encounter, the participants uses the individualized decision aid prior to the clinical encounter to discretely assess HIV risk and build awareness before discussing with their clinician

    Device: PrEP Decision Aid

  • Other
    Generic Information

    Participants randomized to this arm will be asked to watch a CDC-produced video, "PrEP (Pre-Exposure Prophylaxis)" (available online free of charge through CDC website) that will serve as a time- and attention-based control.

    Other: Generic Information

Interventions

  • DevicePrEP Decision Aid

    Patient-facing decision-aid on PrEP that will be enhanced to include various formulations of available PrEP. Can be integrated into sexual and reproductive health clinics as part of counseling.

  • OtherGeneric Information

    Participants will be asked to watch a CDC-produced video, "PrEP (Pre-Exposure Prophylaxis" (available online free of charge through the CDC web site). The video will serve as a time- and attention- based control to the decision aid.

06

What researchers measure

Primary outcomes

  1. PrEP initiation (prescribing)

    Whether PrEP was prescribed (yes/no) in the EHR within the 6-month time frame

    Time frame: 6 months

  2. Feasibility of implementing the enhanced PrEP decision aid in SRH settings, according to the Proctor taxonomy

    Feasibility is defined as the extent to which the enhanced PrEP decision aid can be successfully used in SRH clinic settings (qualitative).

    Time frame: 6 months

  3. Acceptability of the enhanced PrEP decision aid within SRH settings, according to users (Proctor taxonomy)

    Acceptability is defined as the user perception that the enhanced PrEP decision aid is acceptable in SRH settings.

    Time frame: 6 months

  4. Penetration (reach) of the enhanced decision aid within SRH clinics (Proctor taxonomy)

    Penetration (reach) of the intervention, measured by recruitment rate (number of participants enrolled per month)

    Time frame: 6 months

  5. Penetration (reach) of the enhanced decision aid within SRH clinics (Proctor taxonomy)

    Penetration (reach) of the intervention, measured by completion rate (percentage of participants completing 6-month interviews out of those enrolled)

    Time frame: 6 months

  6. Penetration (reach) of the enhanced decision aid within SRH clinics (Proctor taxonomy)

    Penetration (reach) of the intervention, measured by reasons for not meeting inclusion criteria

    Time frame: 6 months

  7. Adoption of the enhanced PrEP decision aid within SRH settings, according to users (Proctor taxonomy)

    Adoption of the enhanced decision aid into SRH clinics, assessed by whether PrEP was discussed during the visit (yes/no)

    Time frame: 6 months

Secondary outcomes

  1. PrEP initiation (dispensing)

    Whether PrEP was dispensed (yes/no) in the EHR within the 6-month time frame

    Time frame: 6 months

  2. PrEP initiation (first use)

    Whether PrEP was started by the patient within the 6 months' time frame (yes/no)

    Time frame: 6 months

  3. PrEP adherence

    Non-pharmacokinetic: (subjective) 3-item self-report with 30-day look-back

    Time frame: 6 months

  4. PrEP adherence

    Non-pharmacokinetic: (objective) pharmacy refill data or injection dates for LAI.

    Time frame: 6 months

  5. PrEP adherence

    Pharmacokinetic: (objective) urine tenofovir levels (units detected/ not detected)

    Time frame: 6 months

  6. PrEP persistence

    Dates of completed PrEP encounters in EHR (i.e., clinic dates)

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Yale Clinical and Community Research
    New Haven, Connecticut 06519, United States
    Recruiting
    • Carolina Price, MPA · Contactcarolina.price@yale.edu · 203-499-8075
    • Jaimie P Meyer, MD · Contactjaimie.meyer@yale.edu · 2037376233
    • Jaimie P Meyer, MD · Principal investigator
    • Sangini S Sheth, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 11 months after the start.

Of 64 non-industry phase 2 interventional studies under HIV Infections, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 74. This study's planned 11 months is below that.

Counting every sponsor, half of 98 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2024
First posted
Nov 12, 2024
StartActual
Mar 11, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Sep 5, 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06684613
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Mar 11, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Sep 5, 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Carolina Price, MPA
Contact
carolina.price@yale.edu
2034998075
Jaimie P Meyer, MD
Contact
jaimie.meyer@yale.edu
2037376233
Jaimie P Meyer, MD
principal investigator · Yale Clinical and Community Research, Yale School of Medicine
Sangini S Sheth, MD
principal investigator · Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion